reMYND

About:

reMYND drives the development of disease-modifying treatments against protein misfolding disorders.

Website: https://www.remynd.com/

Twitter/X: remyndnv

Top Investors: Korys, PMV, BNP Paribas Fortis, KU Leuven, Gemma Frisius Fund

Description:

Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models. They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugs currently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept.